CLEO to Fast Track Development of Ovarian Cancer Test
Filed with ASX · · 4 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced a collaboration with University College London to accelerate the development of its ovarian cancer test by accessing a significant number of high-quality blood samples from a major screening trial. This partnership aims to enhance CLEO's clinical validation program and support two clinical studies focused on pre-surgical and screening applications. The initiative is part of CLEO's broader strategy to deliver its ovarian cancer detection technology to the global market. The announcement highlights the potential impact of CLEO's technology in improving early detection and diagnosis of ovarian cancer.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLEO Receives A$845k Research and Development Tax Incentive
- CLEO Delivers Commercial Development Milestone
- Price Query Response
- CLEO Further Expands Ovarian Cancer Trial with Siles Health
- The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
Later from CLEO Diagnostics
- Cleo Advances with Completion of Alpha Testing
- Corporate Presentation
- CLEO Strengthens FDA Submission - Access to US Biobank
- COV Commences Health Economic Study-Support US Market Entry
- Appendix 4E and 2025 Annual Report
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics